Aeolus Pharmaceuticals Inc.’ AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy

LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced the presentation of data by researchers at Loma Linda University Medical Center, National Jewish Medical and Research Center and Duke University showing that one of the Company’s metalloporphyrin antioxidants, AEOL 10113, demonstrated protection of healthy normal cells in mice with prostate tumor cells treated with radiation therapy. The study also showed that the compound did not interfere with the tumor destruction effects of the radiation therapy.